BioSpace News Archive

Globus Medical, Inc., a leading musculoskeletal solutions company, announced that over 20,000 spine procedures have been performed utilizing the ExcelsiusGPS® Robotic Navigation system.

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today U.S. Food and Drug Administration (FDA) clearance of the Dexcom Partner Web APIs, enabling invited third-party developers to integrate real-time CGM data into their digital health apps and devices.

LeMaitre Vascular, Inc. announced that it will release its second quarter 2021 financial results on Thursday, July 29, 2021, after the market close.

Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reported the results of operations for the three and six months ended May 31, 2021.

FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted to recommend not approving roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, for the treatment of anemia due to chronic kidney disease (CKD) in adult patients.

Pharmaceutical unit dose packaging has gained gigantic popularity as it offers the patients a precise dose of medication as required.

SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), today announced the signing of an agreement that subject to an approval by the Food & Drug Administration (FDA), will allow AZOVA to sell and distribute SQI’s COVID-19 HOME Antibody Test .

The Gastric Balloon market was valued at US$ 67.3 million in 2018 and it is projected to reach US$ 152.1 million by 2027; it is expected to grow at a CAGR of 9.7% from 2019 to 2027.

The transplant diagnostics market was valued at US$ 789.88 million in 2018 and it is projected to reach US$ 1,542.89 million in 2027; it is expected to grow at a CAGR of 7.9% from 2018 to 2027.

Imago BioSciences, Inc., a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms, announced the pricing of its upsized initial public offering of 8,400,000 shares of common stock at a public offering price of $16.00 per share.